Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2000 June; 1(2): 8–13.
Published online 2015 February 19. doi:  10.1208/pt010208
PMCID: PMC2784827

Pramlintide injection drug product robustness studies


The article examines the effects of temperature excursions and actual dose withdrawal on the quality of pramlintide injection, a multidose liquid parenteral formulation. Studies were designed to demonstrate product robustness under conditions that may occur during patient use. Pramlintide %Purity was determined by two high-performance liquid chromatography (HPLC) methods, a reversed-phase (RP-HPLC) and a strong-cation exchange (SCX-HPLC) method. A second RP-HPLC method was used to determine pramlintide potency and the concentration of them-cresol preservative. Antimicrobial preservative effectiveness testing was per USP and European Pharmacopeia (Ph. Eur.). Short-term stability studies were undertaken to probe the effects of the following conditions: 5°C to 40°C and 5°C to −20°C temperature cycling over 10 days; once daily or four-times daily dose withdrawal over 12 or 42 days; and combined 30°C storage and four-times daily dose withdrawal over 42 days. In all cases, pramlintide %Purity and potency values remained essentially unchanged or unchanged relative to controls. Similarly, product appearance, andm-cresol concentration and preservative effectiveness were not significantly affected by the stress conditions used in the 5 studies. Pramlintide injection drug product is extremely robust to challenging stress conditions that may occur during patient use of this multidose product for chronic administration.

Keywords: Pramlintide, Preserved Drug Product, Container Closure Robustness, Temperature Cycling, Preservative Efficacy

Full Text

The Full Text of this article is available as a PDF (64K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Young A, Pittner R, Gedulin B, Vine W, Rink T. Amylin Regulation of carbohydrate metabolism. Biochem Soc Trans. 1995;23:325–331. [PubMed]
2. Scherbaum WA. The role of amylin in the physiology of glycemic control. Experimental and Clinical Endocrinol and Diabetes. 1998;106(2):97–102. doi: 10.1055/s-0029-1211958. [PubMed] [Cross Ref]
3. Amiel S. Amylin and diabetes. Lancet. 1993;341:1249–1250. doi: 10.1016/0140-6736(93)91153-D. [PubMed] [Cross Ref]
4. Janes S, Gaeta L, Beaumont K, Beeley K, Rink T. The selection of pramlintide for clinical evaluation. Diabetes. 1996;45(Suppl 2):235A–235A.
5. Thompson RG, Gottlieb A, Organ K, Kolterman OG. Pramlintide, a human amylin analog reduced post-prandial plasma glucose, insulin and epeptide concentrations in patients with type II diabetes. Diabetic Medicine. 1997;14(7):547–555. doi: 10.1002/(SICI)1096-9136(199707)14:7<547::AID-DIA390>3.0.CO;2-U. [PubMed] [Cross Ref]
6. Thompson RG, Peterson J, Gottlieb A, Mullane J. Effects of pramlintide, an analog of human amylin on plasma glucose profiles in patients with IDDM: results of a multi-center trial. Diabetes. 1997;46(4):632–636. doi: 10.2337/diabetes.46.4.632. [PubMed] [Cross Ref]
7. Brower V. Amylin's pramlintide best of bad bunch of diabetes drugs. Nature Biotechnol. 1997;15(10):935–935. doi: 10.1038/nbt1097-935. [PubMed] [Cross Ref]
8. Hekman C, Demond W, Dixit T, et al. Isolation and identification of peptide degradation products of heat stressed pramlintide injection. Pharmaceutical Research. 1998;15:650–659. doi: 10.1023/A:1011934829263. [PubMed] [Cross Ref]
9. Kenley R, Demond W, L'Italien J, Lokensgard D, Weilersbacher G. Orthogonal HPLC methods for quantitating related substances and degradation products of pramlintide.AAPS PharmSciTech 1(n1) 2000 (|url) [PMC free article] [PubMed]
10. Kenley R, Tracht S, Stepanenko A, Townsend M, L'Italien J. Kinetics of pramlintide degradation in aqueous solution as a function of temperature and p..AAPS PharmSciTech 1(2) 2000 (|url) [PMC free article] [PubMed]
11. International Committee on Harmonization ICH Q5C. “Guideline for Industry: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products”. Section VI.C.1996.
12. Committee for Proprietary Medicinal Products. European Agency for the Evaluation of Medicinal Products. “Note for Guidance on Inclusion of Antioxidants and Antimicrobial Preservatives in Medicinal Products”. Section 8. 1998.
13. Committee for Proprietary Medicinal Products. European Agency for the Evaluation of Medicinal Products. “Note for Guidance on Development Pharmaceutics”. Section 3.3.1., 1998.
14. U.S. Food and Drug Administration Center for Drug Evaluation and Research, Department of Health and Human Services. “Guideline for Submitting Documentation for Packaging for Human Drugs and Biologics”. Section III.B. 1987.
15. International Committee on Hamonization ICH Q5C “Guideline for Industry: Quality of Biotechnological Products: Stability Testing of Biotechnological Biological Products”. Section VI.E. 1996.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists